| Autor: |
Kanno AI; Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brazil., Barbosa MMF; Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brazil.; Universidade de São Paulo, Programa de Pós-Graduação Interunidades em Biotecnologia, São Paulo, Brazil., Moraes L; Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brazil.; Universidade de São Paulo, Programa de Pós-Graduação Interunidades em Biotecnologia, São Paulo, Brazil., Leite LCC; Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brazil. |
| Abstrakt: |
The SARS-CoV-2 coronavirus pandemic calls for coordinated efforts by the scientific community for the development of vaccines. The most advanced strategies have focused on modifications of technologies that were already under development for other viruses, such as SARS, MERS, and even Influenza. Classic and new technologies, such as inactivated and attenuated viruses (non-replicative and replicative), DNA and mRNA vaccines, and nanoparticles containing SARS-CoV-2 antigens, are some of the strategies currently investigated. Although there is a very high expectation for the effectiveness of the most advanced vaccine candidates, there are still no established correlates of protection. Previous experience in vaccine development for other pathogens shows that differences in vaccine formulation can result in diverse immune responses and consequently, different protective properties. Therefore the importance of continuing investigations on a broad range of strategies. Expertise in vaccine development in Brazil was refocused to the new coronavirus. Impressive collaboration between institutions will support further developments until we have available a safe, effective, and economically viable vaccine. Established competence and collaborations will allow preparedness for future challenges and can also be used to address local issues as neglected infectious diseases. |
